Navigation Links
Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
Date:9/7/2018

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology & Laboratory Medicine on August 31, 2018. Download the study here: https://bit.ly/2wMyIVb

Duchenne muscular dystrophy (DMD) is a rare, progressive, and fatal neuromuscular disease caused by dystrophin protein loss in muscle. To support investigational treatment approaches, Flagship applied its expertise and proprietary technology in digital tissue image analysis to develop an immunofluorescent scanning and digital image-analysis solution that enables analysis of all muscle fibers within a biopsy section as well as providing data on each individual fiber.

To validate the MuscleMap approach, the study compared high-powered microscopic field total fiber counts and dystrophin-positive fiber counts obtained by trained pathologists to data produced by the MuscleMap algorithm. The authors note that this work is the first to validate immunofluorescent scanning and digital tissue image analysis workflow with the rigor required to support clinical trials.

“These exciting results will support more effective clinical trials for examining myofibers dystrophin expression by driving a greater level of consistency and detail,” says Trevor D. Johnson, Flagship Biosciences CEO. “Flagship is proud to partner with pharmaceutical and biotech companies in the development of digital image analysis solutions, like MuscleMap, that support the treatment of challenging medical conditions such as DMD.”

Download the study here: https://bit.ly/2wMyIVb

About Flagship Biosciences
Flagship Biosciences Inc. delivers comprehensive tissue profiling for predictive diagnostics in drug therapy using an Artificial Intelligence (AI) enabled computational tissue analysis (cTA®) pathology analytics platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients. For more information on how Flagship accelerates drug development, please visit http://www.flagshipbio.com and follow Flagship on Twitter @FlagshipBio.

Read the full story at https://www.prweb.com/releases/flagship_s_digital_tissue_image_analysis_approach_validated_in_assessment_of_dystrophin_muscle_biopsies_findings_published_in_archives_of_pathology_laboratory_medicine/prweb15739001.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Digital Science & SciBite Join Forces to Harness Big Data for Life Sciences
2. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the March 2013 Digital Edition Now Available Online and in the App Store
3. Simagis Digital Web Pathology Launches Service Provider Network
4. Chemical Publishing Company Partners with Author Cloudware for a Digital eBook Distribution for Water Treatment, Waste Water Treatment, and Cooling Water Treatment Titles
5. New Digital Temperature Controllers with Ramp/Soak Capabilities
6. Three Dispensing Modes Featured in the New Masterflex I/P Digital Brushless Process Drives from Cole-Parmer
7. Bugs eye inspires hemispherical digital camera
8. Digital X-Ray Market worth $4.82 By 2018
9. Simagis Web Pathology Adds Fast Search Capability for Digital Slide Archives
10. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
11. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2019)... ... March 14, 2019 , ... EyeCRO LLC has been awarded ... joins the Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State ... in Oklahoma to receive this prestigious endorsement. The award letter from AAALAC ...
(Date:3/14/2019)... ... 14, 2019 , ... Open registration for the Case Management ... of Case Management,” continues as CMSA makes plans to host the annual event ... management industry conference serving the educational and networking needs of case and care ...
(Date:3/14/2019)... ... 13, 2019 , ... Murrieta Genomics , the genomic sequencing business incubator, ... broader business experience to bear as genomic sequencing startups build their business models. , ... expertise that our Advisory Board brings to the table. Many of these experts would ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... solution for preclinical research organizations. It is a low code, GDPR/21 CFR ... and facilities, innovative technology-driven automated data capture and seamless data and information ...
Breaking Biology Technology:
(Date:4/16/2019)... ... April 16, 2019 , ... The International Society ... The 2019 ISPE Biopharmaceutical Manufacturing Conference , on 18–20 June and The ... one of the most influential bio hubs, Boston, Massachusetts USA, these concurrent events ...
(Date:4/9/2019)... ... ... The McLeod Center for Cancer Treatment and Research has been named ... by an independent, third-party panel of experts in radiation oncology, patient safety and treatment ... is the only such cancer center in South Carolina. The hospital also represents one ...
(Date:4/4/2019)... ... April 02, 2019 , ... Researchers ... present results demonstrating that RNA genetic testing (RGT), as a supplement to DNA ... as a Top Rated poster, is one of 13 presentations at the 2019 ...
Breaking Biology News(10 mins):